{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:40:28Z","timestamp":1787499628508,"version":"build-2736575974"},"reference-count":53,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2025,5,5]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>The misuse of illicit drugs and prescription medications may cause neurological complications from overdose, withdrawal and long-term chronic misuse. Drug-use disorder has become particularly important and complex because of different patterns of presentation associated with new psychoactive substances and the growing misuse of opioids, synthetic cannabinoids and stimulants. We review worldwide demographic data of drug-use disorder and discuss the individual classes of agents, newer developments relating to understanding the mechanisms of action and the patterns of administration, usage, toxicity and withdrawal. We consider the difficulties in assessment and the specific acute syndromes of toxicity that present with neurological manifestations. We review the neurological patterns of longer-term complications and consider the effects of drug misuse-related trauma, infection, seizures, stroke, toxic leucoencephalopathy, cognitive impairment, movement disorders and neuromuscular complications. The neurological consequences of drug-use disorder disproportionately affect the young and can have devastating effects on innocent lives. It is essential that neurologists recognise acute toxicity early and understand the longer-term consequences of drug-use disorder.<\/jats:p>","DOI":"10.1136\/pn-2023-003796","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:20:37Z","timestamp":1748337637000},"page":"411-421","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Neurological aspects of drug misuse"],"prefix":"10.1136","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-714X","authenticated-orcid":false,"given":"Robin S","family":"Howard","sequence":"first","affiliation":[{"name":"Guy's and St. Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Holmes","sequence":"additional","affiliation":[{"name":"Guy's and St. Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dargan","sequence":"additional","affiliation":[{"name":"Guy's and St. Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025091212001210000_25.5.411.1","first-page":"iii9","article-title":"Recreational drugs and their neurological consequences","volume":"75 Suppl 3","author":"Enevoldson","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025091212001210000_25.5.411.2","first-page":"181","article-title":"Neurotoxicology and drug-related disorders","volume":"145","author":"Weis","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"2025091212001210000_25.5.411.3","unstructured":"Watson RR , Zibadi S . Addictive substances and neurological disease. Academic Press, 2017."},{"key":"2025091212001210000_25.5.411.4","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2011-000062"},{"key":"2025091212001210000_25.5.411.5","unstructured":"United Nations Office of Drugs and Crime . World drug review. 2021. Available: https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2023.html"},{"key":"2025091212001210000_25.5.411.6","unstructured":"DEA Joint Intellegence Report . The growing threat of xylazine and its mixture with illicit drugs. dea.gov; 2022."},{"key":"2025091212001210000_25.5.411.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2304991"},{"key":"2025091212001210000_25.5.411.8","unstructured":"ONS data and analysis. Drug misuse in England and Wales: year ending. 2023. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/articles\/drugmisuseinenglandandwales\/yearendingmarch2023"},{"key":"2025091212001210000_25.5.411.9","unstructured":"Scottish Government . Suspected drug deaths in Scotland: October to December 2023. 2023 Available: https:\/\/www.gov.scot\/publications\/suspected-drug-deaths-scotland-october-december-2023"},{"key":"2025091212001210000_25.5.411.10","unstructured":"GDS . Global drug survey 2022. Global Drug Survey; 2022. Available: www.globaldrugsurvey.com"},{"key":"2025091212001210000_25.5.411.11","unstructured":"European drug report 2024: trends and developments. Available: https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024_en"},{"key":"2025091212001210000_25.5.411.12","unstructured":"Early Warning Advisory on New Psychoactive Substances . UNODC early warning advisory (EWA) on new psychoactive substances (NPS). 2024 Available: https:\/\/www.unodc.org\/LSS\/Home\/NPS"},{"key":"2025091212001210000_25.5.411.13","unstructured":"EUDA European Union drugs agency . European drug report 2024. New psychoactive substances \u2013 the current situation in Europe. 2024. Available: https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024\/new-psychoactive-substances_en"},{"key":"2025091212001210000_25.5.411.14","unstructured":"United Nations Office on Drugs and Crime (UNODC) . Terminology and information on drugs. 3rd edn. United nations, 2016. Available: https:\/\/www.unodc.org\/documents\/scientific\/Terminology_English.pdf"},{"key":"2025091212001210000_25.5.411.15","doi-asserted-by":"publisher","DOI":"10.1136\/injuryprev-2020-043968"},{"key":"2025091212001210000_25.5.411.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2212152"},{"key":"2025091212001210000_25.5.411.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1407928"},{"key":"2025091212001210000_25.5.411.18","unstructured":"UNODC . The emergence of semi-synthetic cannaboids. 2024 Available: https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/b11f43d9-3a70-436a-930e-65ece3ff4125#:~:text=Since%202022%2C%20a%20total%20of,tetrahydrocannabidiol%20(H4%2DCBD)"},{"key":"2025091212001210000_25.5.411.19","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . Medical use of cannabis and cannabinoids: questions and answers for policymaking. 2018 Available: https:\/\/www.emcdda.europa.eu\/publications\/rapid-communications\/medical-use-of-cannabis-and-cannabinoids-questions-and-answers-for-policymaking_en"},{"key":"2025091212001210000_25.5.411.20","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002058"},{"key":"2025091212001210000_25.5.411.21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1192\/bjp.2018.1","article-title":"Cannabis and psychosis: what do we know and what should we do?","volume":"212","author":"Colizzi","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2025091212001210000_25.5.411.22","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . Synthetic cannabinoids. 2024 Available: https:\/\/www.emcdda.europa.eu\/topics\/synthetic-cannabinoids_en"},{"key":"2025091212001210000_25.5.411.23","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13070990","article-title":"Toxicity of Synthetic Cannabinoids in K2\/Spice: A Systematic Review","volume":"13","author":"de Oliveira","year":"2023","journal-title":"Brain Sci"},{"key":"2025091212001210000_25.5.411.24","unstructured":"Conan Doyle A . The sign of four. London: Spencer Blackett, 1890."},{"key":"2025091212001210000_25.5.411.25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ncl.2020.08.005","article-title":"Neurotoxicology Syndromes Associated with Drugs of Abuse","volume":"38","author":"Caplan","year":"2020","journal-title":"Neurol Clin"},{"key":"2025091212001210000_25.5.411.26","unstructured":"UNDOC Early warning Advisory on New Psychoactive Substances . UNODC early warning advisory (EWA) on new psychoactive substances (NPS). 2024. Available: https:\/\/www.unodc.org\/LSS\/Home\/NPS"},{"key":"2025091212001210000_25.5.411.27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s11606-014-2802-4","article-title":"Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones","volume":"29","author":"Khullar","year":"2014","journal-title":"J Gen Intern Med"},{"key":"2025091212001210000_25.5.411.28","unstructured":"UNODC . Current NPS threats 2021. Benzodiazepine-type NPS. Available: https:\/\/www.unodc.org\/documents\/scientific\/NPS_threats-IV.pdf"},{"key":"2025091212001210000_25.5.411.29","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . Synthetic cathinones. n.d. Available: https:\/\/www.emcdda.europa.eu\/topics\/synthetic-cathinones_en"},{"key":"2025091212001210000_25.5.411.30","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . GHB and its precursor GBL: an emerging trend case study. 2008 Available: https:\/\/www.euda.europa.eu\/publications\/thematic-papers\/ghb_en"},{"key":"2025091212001210000_25.5.411.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-015-0024-7","article-title":"Designer drugs 2015: assessment and management","volume":"10","author":"Weaver","year":"2015","journal-title":"Addict Sci Clin Pract"},{"key":"2025091212001210000_25.5.411.32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/164_2019_260","article-title":"Newly Emerging Drugs of Abuse","volume":"258","author":"Tamama","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"2025091212001210000_25.5.411.33","unstructured":"World Drug review . Recent developments involving psychedelics. 2023. Available: https:\/\/www.unodc.org\/res\/WDR-2023\/WDR23_B3_CH2_psychedelics.pdf"},{"key":"2025091212001210000_25.5.411.34","unstructured":"UNDOC Early warning Advisory on New Psychoactive Substances . Phenyclidine-type substances. 2024. Available: https:\/\/www.unodc.org\/LSS\/SubstanceGroup\/Details"},{"key":"2025091212001210000_25.5.411.35","unstructured":"Orhurhu VJ , Vashisht R , Claus LE . Ketamine toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2025. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541087\/"},{"key":"2025091212001210000_25.5.411.36","unstructured":"Perry H . Inhalent abuse in children and adolescents. UpToDate; 2024."},{"key":"2025091212001210000_25.5.411.37","doi-asserted-by":"crossref","unstructured":"Howard R , Al-Mayhani T , Carr A , et al . Toxic, metabolic and hysical insults to the nervous system. In: Howard R , Kullmann D , Werring D , eds. Neurology: a queen square textbook. 3rd edn. John Wiley & Sons Ltd, 2024: 903\u201345.doi:10.1002\/9781119715672","DOI":"10.1002\/9781119715672.ch26"},{"key":"2025091212001210000_25.5.411.38","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcs016"},{"key":"2025091212001210000_25.5.411.39","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.047134"},{"key":"2025091212001210000_25.5.411.40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4103\/aian.AIAN_446_18","article-title":"Toxic Leukoencephalopathy due to Inhalational Heroin Abuse","volume":"23","author":"Kashyap","year":"2020","journal-title":"Ann Indian Acad Neurol"},{"key":"2025091212001210000_25.5.411.41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12883-015-0467-1","article-title":"Multifocal leukoencephalopathy in cocaine users: a report of two cases and review of the literature","volume":"15","author":"Vosoughi","year":"2015","journal-title":"BMC Neurol"},{"key":"2025091212001210000_25.5.411.42","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091295","article-title":"A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse","volume":"8","author":"Tsatsakis","year":"2019","journal-title":"J Clin Med"},{"key":"2025091212001210000_25.5.411.43","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.011417"},{"key":"2025091212001210000_25.5.411.44","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.000749"},{"key":"2025091212001210000_25.5.411.45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316071"},{"key":"2025091212001210000_25.5.411.46","first-page":"e1","article-title":"Clinical characteristics and outcomes of methamphetamine-associated intracerebral hemorrhage","volume":"93","author":"Swor","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2025091212001210000_25.5.411.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2023.07.015"},{"key":"2025091212001210000_25.5.411.48","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2023-003724"},{"key":"2025091212001210000_25.5.411.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.02.005"},{"key":"2025091212001210000_25.5.411.50","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3233\/JPD-179006","article-title":"The MPTP Story","volume":"7","author":"Langston","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"2025091212001210000_25.5.411.51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8040551","article-title":"Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis","volume":"8","author":"Oussalah","year":"2019","journal-title":"J Clin Med"},{"key":"2025091212001210000_25.5.411.52","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2022-003631"},{"key":"2025091212001210000_25.5.411.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45031-4","article-title":"Incidence of rhabdomyolysis occurrence in psychoactive substances intoxication: a systematic review and meta-analysis","volume":"13","author":"Amanollahi","year":"2023","journal-title":"Sci Rep"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2023-003796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:00:45Z","timestamp":1757703645000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2023-003796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/pn-2023-003796"],"URL":"https:\/\/doi.org\/10.1136\/pn-2023-003796","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}